Analysis: human immunity to Cas9 bigger #CRISPR therapeutic hurdle than off-targets? - The Niche
Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially [...]